TY - JOUR
T1 - A case-control study of HIV seroconversion in health care workers after percutaneous exposure
AU - Cardo, Denise M.
AU - Culver, David H.
AU - Ciesielski, Carol A.
AU - Srivastava, Pamela U.
AU - Marcus, Ruthanne
AU - Abiteboul, Dominique
AU - Heptonstall, Julia
AU - Ippolito, Giuseppe
AU - Lot, Florence
AU - McKibben, Penny S.
AU - Bell, David M.
PY - 1997/11/20
Y1 - 1997/11/20
N2 - Background: The average risk of human immunodeficiency virus (HIV) infection after percutaneous exposure to HIV-infected blood is 0.3 percent, but the factors that influence this risk are not well understood. Methods: We conducted a case-control study of health care workers with occupational, percutaneous exposure to HIV-infected blood. The case patients were those who became seropositive after exposure to HIV, as reported by national surveillance systems in France, Italy, the United Kingdom, and the United States. The controls were health care workers in a prospective surveillance project who were exposed to HIV but did not seroconvert. Results: Logistic- regression analysis based on 33 case patients and 665 controls showed that significant risk factors for seroconversion were deep injury (odds ratio=15; 95 percent confidence interval, 6.0 to 41), injury with a device that was visibly contaminated with the source patient's blood (odds ratio=6.2; 95 percent confidence interval, 2.2 to 21), a procedure involving a needle placed in the source patient's artery or vein (odds ratio=4.3; 95 percent confidence interval, 1.7 to 12), and exposure to a source patient who died of the acquired immunodeficiency syndrome within two months afterward (odds ratio=5.6; 95 percent confidence interval, 2.0 to 16). The case patients were significantly less likely than the controls to have taken zidovudine after the exposure (odds ratio= 0.19; 95 percent confidence interval, 0.06 to 0.52). Conclusions: The risk of HIV infection after percutaneous exposure increases with larger with a larger volume of blood and, probably, a higher titer of HIV in the source patient's blood. Postexposure prophylaxis with zidovudine appears to be protective.
AB - Background: The average risk of human immunodeficiency virus (HIV) infection after percutaneous exposure to HIV-infected blood is 0.3 percent, but the factors that influence this risk are not well understood. Methods: We conducted a case-control study of health care workers with occupational, percutaneous exposure to HIV-infected blood. The case patients were those who became seropositive after exposure to HIV, as reported by national surveillance systems in France, Italy, the United Kingdom, and the United States. The controls were health care workers in a prospective surveillance project who were exposed to HIV but did not seroconvert. Results: Logistic- regression analysis based on 33 case patients and 665 controls showed that significant risk factors for seroconversion were deep injury (odds ratio=15; 95 percent confidence interval, 6.0 to 41), injury with a device that was visibly contaminated with the source patient's blood (odds ratio=6.2; 95 percent confidence interval, 2.2 to 21), a procedure involving a needle placed in the source patient's artery or vein (odds ratio=4.3; 95 percent confidence interval, 1.7 to 12), and exposure to a source patient who died of the acquired immunodeficiency syndrome within two months afterward (odds ratio=5.6; 95 percent confidence interval, 2.0 to 16). The case patients were significantly less likely than the controls to have taken zidovudine after the exposure (odds ratio= 0.19; 95 percent confidence interval, 0.06 to 0.52). Conclusions: The risk of HIV infection after percutaneous exposure increases with larger with a larger volume of blood and, probably, a higher titer of HIV in the source patient's blood. Postexposure prophylaxis with zidovudine appears to be protective.
UR - http://www.scopus.com/inward/record.url?scp=0030692781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030692781&partnerID=8YFLogxK
U2 - 10.1056/NEJM199711203372101
DO - 10.1056/NEJM199711203372101
M3 - Article
C2 - 9366579
AN - SCOPUS:0030692781
VL - 337
SP - 1485
EP - 1490
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 21
ER -